- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.04. | GRI Bio, Inc.: GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions | 1 | GlobeNewswire (USA) | ||
| 17.02. | GRI Bio, Inc.: GRI Bio CEO, Marc Hertz, Featured in Virtual Investor "What This Means" Segment | 1 | GlobeNewswire (USA) | ||
| 04.02. | GRI Bio reports FY results | 1 | Seeking Alpha | ||
| 04.02. | GRI Bio reports $8.2 million cash position, extends runway into Q1 2027 | 2 | Investing.com | ||
| 04.02. | GRI Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 04.02. | GRI Bio, Inc.: GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights | 220 | GlobeNewswire (Europe) | Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026 Balance sheet strengthened to fund operations... ► Artikel lesen | |
| 30.01. | GRI Bio, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| GRI BIO Aktie jetzt für 0€ handeln | |||||
| 28.01. | GRI Bio reports positive gene expression data for IPF drug candidate | 2 | Investing.com | ||
| 28.01. | GRI Bio, Inc.: GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF | 218 | GlobeNewswire (Europe) | Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio"... ► Artikel lesen | |
| 28.01. | GRI Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.01. | GRI Bio, Inc.: GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures | 2 | GlobeNewswire (USA) | ||
| 22.01. | GRI Bio Announces Reverse Stock Split To Regain Minimum Bid Price Nasdaq Compliance | - | RTTNews | ||
| 21.01. | GRI Bio announces 1-for-28 reverse share split | 1 | Seeking Alpha | ||
| 21.01. | GRI Bio: Aktienzusammenlegung im Verhältnis 1:28 soll Verbleib an der Nasdaq sichern | 6 | Investing.com Deutsch | ||
| 21.01. | GRI Bio announces 1-for-28 reverse stock split to regain Nasdaq compliance | 1 | Investing.com | ||
| 21.01. | GRI Bio, Inc.: GRI Bio Announces Reverse Stock Split | 505 | GlobeNewswire (Europe) | GRI's common stock is expected to begin trading on a post-split adjusted basis on January 26, 2026 LA JOLLA, CA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company")... ► Artikel lesen | |
| 15.01. | GRI Bio: Aktionäre stimmen für Aktienzusammenlegung - Nasdaq-Anforderungen wieder erfüllt | 2 | Investing.com Deutsch | ||
| 15.01. | GRI Bio, Inc. - 8-K, Current Report | 6 | SEC Filings | ||
| 09.01. | GRI Bio stockt ATM-Kapitalprogramm auf 7,38 Mio. US-Dollar auf | 10 | Investing.com Deutsch | ||
| 08.01. | GRI Bio: Aktie legt nach positiven Phase-2a-Daten für Lungenfibrose-Wirkstoff zu | 2 | Investing.com Deutsch |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,15 | +0,22 % | Insiderverkäufe, Kaufempfehlungen und KI-Fantasie: BioNTech, Evotec, Vidac Pharma Aktie. | Insiderverkäufe bei Vidac Pharma. Dies ist jedoch kein Alarmsignal, sondern bietet eher eine Einstiegschance. Das Unternehmen arbeitet an einer revolutionären Krebstherapie. In 2026 sollen wichtige... ► Artikel lesen | |
| EVOTEC | 5,350 | -0,93 % | ACHTUNG bei Evotec: Warum erfahrene Anleger zum Wochenstart die Reißleine ziehen - Was erfahrene Anleger jetzt analysieren | ||
| AMGEN | 295,40 | +0,44 % | Amgen Announces Retirement Of David M. Reese, Executive Vice President And Chief Technology Officer | Organizational Changes Further Emphasize Integration of Biology and Technology
THOUSAND OAKS, Calif., April 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,050 | +0,18 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,324 | -1,52 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Grant of Restricted Stock Units | Montreal, Quebec--(Newsfile Corp. - April 24, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,380 | -1,55 % | NurExone Biologic: 100% Erfolgsquote bei Querschnittlähmung! | ||
| ABIVAX | 96,10 | -1,64 % | EQS-News: ABIVAX: Abivax to Present Data on Obefazimod at Digestive Disease Week | EQS-News: ABIVAX
/ Key word(s): Conference
Abivax to Present Data on Obefazimod at Digestive Disease Week
22.04.2026 / 22:05 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| IBIO | 1,439 | +0,07 % | iBio (IBIO) Receives Regulatory Clearance to Initiate Phase 1 Trial of IBIO-600 | ||
| ARROWHEAD PHARMACEUTICALS | 63,80 | +1,14 % | Sanofi, Arrowhead, Novartis among winners of EU recommendations this week | ||
| VOYAGER THERAPEUTICS | 3,520 | +8,71 % | Voyager Therapeutics CFO resigns; Robin Swartz takes financial charge | ||
| CYBIN | 4,760 | -0,63 % | Chutes & Ladders-Helus shuffles out CEO after two months, adds experience to science board | ||
| CAPRICOR | 29,250 | -2,82 % | Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting | ||
| OPGEN | 1,568 | 0,00 % | AEI CapForce II Investment Corp - S-1/A, General form for registration of securities | ||
| APELLIS PHARMACEUTICALS | 34,860 | -0,20 % | Apellis Pharmaceuticals is the most overbought healthcare stock as Q1 earnings roll on | ||
| MEREO BIOPHARMA | 0,252 | +1,61 % | Mereo BioPharma Group plc: Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights | Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing Cash of $41.0 million as of December 31, 2025, expected to provide runway into... ► Artikel lesen |
GRI BIO INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -2,53 % bei einem Aktienkurs von 2,310 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GRI BIO INC finden Sie auf Wallstreet Online.